Here are five points:
1. The study was designed to determine if using a risk-based VTE chemoprophylaxis protocol would improve prevention of deep vein thrombosis and pulmonary embolism, quality metrics and bleeding-related complications in patients undergoing total joint arthroplasty.
2. Researchers evaluated 2,611 patients divided into two cohorts — one consisting of 1,203 patients who had previously been treated with an aggressive chemoprophylaxis protocol and the second consisting of a risk-stratified group of patients either undergoing treatment with prophylactic synchronized mobile compression and aspirin or aggressive chemoprophylaxis.
3. The study showed that patients in the second cohort had a lower incidence of VTE than the group treated with anticoagulation and also experienced fewer adverse events, readmissions, infections and bleeding-related complications.
4. Additionally, hospital costs were significantly lower in the second cohort.
5. Medical Compression Systems’ ActiveCare is a non-pharmaceutical, mobile compression device that aims to provide effective and safe prevention against deep vein thrombosis.
More articles on orthopedics:
Orthopedic surgeon to know: Dr. James Andrews of Andrews Institute for Orthopaedics & Sports Medicine
Cookeville Regional Medical in Tennessee honored for orthopedic care: 4 things to note
Global biomaterial market strong in orthopedics: 4 observations
